Anticoagulation in COVID-19: why, what, and when
Coronavirus disease-2019, which was declared by the WHO as a global pandemic in March 2020, was seen to be associated with high incidence of thromboembolic complication. The use of prophylactic anticoagulation was seen to have a survival benefit, especially in high-risk patients. The use of higher t...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
| Series: | Egyptian Journal of Chest Disease and Tuberculosis |
| Subjects: | |
| Online Access: | http://www.ejcdt.eg.net/article.asp?issn=0422-7638;year=2021;volume=70;issue=5;spage=12;epage=15;aulast=Taema |
| Summary: | Coronavirus disease-2019, which was declared by the WHO as a global pandemic in March 2020, was seen to be associated with high incidence of thromboembolic complication. The use of prophylactic anticoagulation was seen to have a survival benefit, especially in high-risk patients. The use of higher than standard-dose prophylaxis anticoagulation in critically ill patients may be warranted. There is no recommendation regarding the use of therapeutic dose anticoagulation, except for very high-risk patients only transiently until proving or disproving the presence of thromboembolic complications. |
|---|---|
| ISSN: | 0422-7638 2090-9950 |